828 results on '"Chapman, Arlene B."'
Search Results
2. Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers
3. The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD
4. Emerging Role of Clinical Genetics in CKD
5. Agreement of Food Records and 24-Hour Urine Studies in Clinical Practice
6. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument
7. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics
8. Temporal assessment of magnetic resonance imaging radiomic features to predict renal function decline in patients with autosomal dominant polycystic kidney disease
9. Circulating microRNA Biomarkers of Thiazide Response in Hypertension
10. Tolvaptan in ADPKD Patients With Very Low Kidney Function
11. Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone
12. Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
13. Cardiac Localized Polycystin-2 plays a Functional Role in Natriuretic Peptide Production and its Absence Contributes to Hypertension
14. A Genetic Response Score for Hydrochlorothiazide Use
15. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach
16. Magnetic resonance imaging preprocessing and radiomic features for classification of autosomal dominant polycystic kidney disease genotype
17. All Patients with ADPKD Should Undergo Screening for Intracranial Aneurysms: COMMENTARY
18. Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation
19. Pharmacometabolomics reveals racial differences in response to atenolol treatment.
20. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial
21. Abstract 15986: Plasma Microrna Profiling Reveals Potential Biomarkers of Thiazide Response
22. Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease
23. Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response
24. A Physiologic Approach to the Pharmacogenomics of Hypertension
25. Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy
26. Polycystic and Other Cystic Kidney Diseases
27. Contributors
28. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort
29. Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide
30. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)
31. Liver Involvement in Early Autosomal-Dominant Polycystic Kidney Disease
32. Effects of Bardoxolone Methyl in Alport Syndrome
33. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents
34. Identification and characterization of circulating immune complexes in IgA nephropathy
35. Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients
36. Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients
37. Chapter 39 - Polycystic and Other Cystic Kidney Diseases
38. Baseline predictors of central aortic blood pressure: A PEAR substudy
39. Health-Related Quality of Life in Patients With Autosomal Dominant Polycystic Kidney Disease and CKD Stages 1-4: A Cross-sectional Study
40. Protein kinase Cα deletion causes hypotension and decreased vascular contractility
41. New treatment paradigms for ADPKD: moving towards precision medicine
42. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
43. Autosomal dominant polycystic kidney disease
44. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial
45. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies
46. Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States
47. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease
48. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression
49. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response
50. Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.